St Patrick's Mercy Home
St. John's, Newfoundland and Labrador, Canada
NCT Number: NCT03091153
This study will develop, implement and evaluate a deprescribing initiative at a Canadian Long Term Care (LTC) Facility. Residents currently undergo an annual medication review as part of the clinical pharmacy services provided in the LTC facility. For this study, eligible residents will be randomized to receive either a deprescribing focused medication review or usual care.
The deprescribing focused medication therapy assessments will be done on half of the 143 residents residing on the second and third floors of the facility. The other half of residents will serve as the control group and continue to receive their annual medication review and regular care from the attending physicians and nurses.
The deprescribing intervention will be delivered by final year pharmacy students completing their practice experiences, under the supervision of clinical pharmacists at the LTC facility and clinical pharmacists from Memorial University's Medication Therapy Services (MTS) Clinic. Currently the clinic has a well developed procedure for providing in depth medication therapy reviews for residents of the community, upon referral by their primary care physician. Students will adapt this model of medication review to have a stronger deprescribing focus and be applicable to elderly residents of a LTC facility. The intervention will consist of an in depth medication therapy review with a focus on identifying any medications that may no longer be required or are deemed to be inappropriate or potentially unsafe in the elderly based on currently guidelines/criteria. The students will work closely with members of the resident's care team on a daily basis, as well as the resident and their family, to develop and implement a deprescribing plan.
Looking for future studies?
Notify Me65 year and older
All sexes
Interventional
Not applicable
St. John's, Newfoundland and Labrador, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
(all of the following):
Exclusion criteria
(any of the following):
In depth medication review with a focus on deprescribing
Time frame: 3 and 6 months after receiving intervention
Measured using facility medication logs and patient health records
Time frame: 3 and 6 months after receiving the intervention
Measured using patient health records
Time frame: 3 and 6 months after receiving the intervention
Measured using facility fall report logs
Time frame: 3 and 6 months after receiving the intervention
Measured using patient health records
Time frame: 3 and 6 months after receiving the intervention
Measured using Cognitive Performance Scale (CPS) obtained from Resident Assessment Instrument (RAI) MDS 2.0
Time frame: baseline, 3 and 6 months after receiving the intervention
Measured using bowel chart data for the 14 days prior to the assessment date
Time frame: 3 and 6 months after receiving the intervention
Measured using the Activities of Daily Living Scale (ADL) obtained from RAI MDS 2.0
Time frame: 3 and 6 months after receiving the intervention
Measured using the Changes in Health, End-Stage Disease and Signs and Symptoms (CHESS) Score obtained from RAI MDS 2.0
Time frame: 3 and 6 months after receiving the intervention
Measured using Index of Social Engagement (ISE) Score obtained from RAI MDS 2.0
Time frame: 3 and 6 months after receiving the intervention
Measured using the Aggressive Behaviour Scale (ABS) obtained from RAI MDS 2.0
Time frame: 3 and 6 months after receiving the intervention
Measured using the Pain Scale obtained from RAI MDS 2.0
Memorial University of Newfoundland
Other
Impact of a Deprescribing Intervention on Nursing Home Residents: a Randomized Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05899114
Medication Review, Polypharmacy
Nijmegen, Gelderland, Netherlands
View Trial DetailsNCT04938648
Alzheimer Disease, Alzheimer Disease and Related Dementias
Aurora, Colorado, United States
View Trial DetailsNCT05091879
Pharmacogenomic Testing, Polypharmacy
Danville, Pennsylvania, United States
View Trial DetailsNCT06383364
Behavior, Empowerment
Aabenraa, Southern Denmark, Denmark
View Trial Details